The Pathway to Personalized Medicine

What is Personalized Medicine?

Every individual’s disease is different. Personalized medicine strives to provide the right medicine for the right patient with the lowest toxicity. Personalized cancer therapy using proteomics involves molecular profiling of the patient’s cancer cells to map the susceptible drug targets and thereby guide therapy. Research, like that being done by the Center for Applied Proteomics and Molecular Medicine, provides strategies for personalized treatment with the goal of providing physicians key missing molecular information about the disease in each of their patients and improving the quality of life for patients.

CAPMM Mission

The Center for Applied Proteomics and Molecular Medicine’s mission is to: a) create new technologies and make basic science discoveries in the field of disease pathogenesis b) apply these discoveries and technologies to create and implement strategies for disease prevention, early diagnosis and individualized therapy. The primary emphasis of our disease research is cancer, but new technologies developed in the center are being applied to a number of important human diseases including cardiovascular disease, diabetes, and obesity, as well as liver, ocular, neurodegenerative and infectious diseases.

2015 RPPA Global Workshop

2015 RPPA Global Workshop

Spots to Solutions: Using RPPA as a tool to answer biological and clinical questions

The 5th annual Reverse Phase Protein Array (RPPA) Global Workshop was hosted at George Mason University, Manassas, Virginia on October 12-13, 2015. The methodology and applications for the RPPA technology is constantly evolving. Therefore, pioneers of the technology, experienced users and researchers interested in incorporating the RPPA technology into their portfolio gathered at the RPPA Global Workshop to discuss the technology’s applications for making advancements in personalized medicine; identifying therapeutic targets; discovering and validating biomarkers; and answering other biological questions. They continued to build on the knowledge exchanged at the previous meetings in Houston (USA) 2011, Edinburgh (UK) 2012, Kobe (Japan) 2013, and Paris (France) 2014. Furthermore, academic and industry representatives guided future directions by exploring 1) hot areas in translational science, 2) combination of RPPA with other technologies to answer questions in new fields, 3) FDA policy encompassing development of laboratory tests and the desire to combine diagnostic markers with therapeutics, and 4) funding opportunities to support studies utilizing RPPA. Free exchange of knowledge was shared in workshops, presentations, and technology showcases. The 2016 RPPA Workshop is being held in Germany on September 25-27.

Clinical Trials

Clinical Trials

Successful Side-Out Metastatic Breast Cancer Clinical Trial is Expanding

The Side-Out Metastatic Breast cancer trial was announced at the annual meeting of the American Society of Clinical Oncology (ASCO) and is expected to expand into phase two this month.

ASCO Poster Presentation

The pilot study was the first of its kind to utilize novel protein activation mapping technology along with the genomic fingerprint of cancer as a way to find the most effective treatment. Results indicate that while prior standard chemotherapy failed the 25 women who participated in the 2.5 year pilot study, nearly half of the patients enrolled in the Side-Out trail had at least a 30 percent increase in progression-free survival.

This molecular approach creates opportunities for new therapies. For example, if a breast tumor shares the same protein pathway activation shared with lung cancer, then the drug developed to hit that target for lung cancer can be used now for breast cancer. The pilot study included only FDA-approved drugs currently on the market. Additional studies are expected to fold in new drugs as they become available with experimental drug.

Hear what patients and a treating physician has to say: Funded by Volleyball Tournaments, Breast Cancer Pilot Study Succeeds

Based on the results of this trial, CAPMM and the Side-Out Foundation are expanding this study to a new trial that is set to launch within the next month.

Featured Video


Student-developed diagnostics could change tuberculosis detection, treatment
04/24/17 |
Ceres Wins $750K DARPA Grant to Develop Zika, Pathogens Tests
02/23/17 | Media Coverage
Tip sheet: Five ways Mason is Knocking Breast Cancer Research out of the Park
11/01/16 | Media Coverage
Mason Researchers Launch Third Phase of Breast Cancer Trial
10/12/16 | Media Coverage
Multi-million dollar financing helps bring Mason research to cancer patients
07/13/16 | Media Coverage
Class of 2016: Discipline and focus serve biology student in the lab and on the court
05/25/16 | Media Coverage
A new test for Lyme disease comes from an unlikely source: a summer intern
05/02/16 | Media Coverage
Researchers Discover Early Lyme Disease Detection
02/25/16 | Media Coverage
Lyme Disease is no Match for Mason Researchers
02/05/16 | Media Coverage
The Side-Out Protocol: A Scientist’s Perspective
01/12/16 | CAPMM Blog
New Patent Paves Way for Breast Cancer Prevention
11/23/15 | Media Coverage
Espina Found Inspiration for Cancer Research as a Fifth-Grader
11/23/15 | Media Coverage
Get Out and Play This Holiday Season: New Research Shows Parents Play Vital Role in Molding Future Scientists
12/08/14 | Media Coverage
Ceres to develop new method for detecting the presence of Ebola virus in saliva
12/08/14 | Media Coverage
Side-Out Story
08/20/14 |
Dyes Used to Paint New Picture of Disease
07/22/14 | Press Releases
Va. girl's science project becomes medical advancement
07/17/13 | Media Coverage
Taking the mystery out of Lyme disease
07/17/13 | Media Coverage
Funded by Volleyball Tournaments, Breast Cancer Pilot Study Succeeds
06/05/13 | Media Coverage
Local Legislators Meet with Mason Lyme Disease Researchers
05/15/13 | Media Coverage